peptide p140 p140 - P140 peptidefor lupus P140 P140 Peptide: A Novel Immunomodulator for Autoimmune Diseases

P140 peptidefor sale online The peptide P140 has emerged as a significant therapeutic candidate for autoimmune diseases, particularly systemic lupus erythematosus (SLE)The Spliceosomal Phosphopeptide P140 Controls the Lupus .... This synthetic peptide, derived from the human spliceosomal protein U1-70K, specifically targets and modulates aberrant immune responses, offering a novel approach to immunotherapy. The research surrounding P140 peptide indicates its potential to restore immune homeostasis by depleting hyper-activated autoreactive T and B cells.

Understanding P140 Peptide: Origin and Mechanism

The P140 peptide is a 21-mer fragment (sequence 131-151) of the U1-70K protein, which is a component of the spliceosome. Notably, P140 is phosphorylated at the Ser140 position, a modification that is crucial for its biological activity作者：N Schall·2022·被引用次数：10—Data indicate thatP140acts by depleting hyper-activated autoreactive T and B cells and restores normal immune homeostasis.. This peptide has demonstrated the ability to bind to the chaperone protein HSPA8/HSC70. This interaction is significant as increased expression of HSC70 has been observed in patients with lupusForigerimod - ImmuPharma. Alternative Names: CEP-33457; IPP-201101; Lupuzor;peptide P140; Rigerimod; SyB 1001. Latest Information Update: 03 Dec 2024. Price .... By binding to HSC70, the P140 peptide effectively blocks its function, leading to a reduction in autophagic processes and a decrease in the overexpression of HLA class II molecules in human lupus B cellsRandomized, Double-Blind, Placebo-Controlled Studies of .... This blockade also enhances peripheral blood lymphocyte apoptosis and diminishes autoepitope recognition by T cells, thereby reducing autoreactivity.作者：S Muller·2008·被引用次数：226—Objective. To assess the safety, tolerability, and efficacy of spliceosomalpeptide P140(IPP-201101; sequence 131–151 of the U1-70K protein ...

Clinical Applications and Evidence

The therapeutic potential of P140 peptide, also known by its investigational names Lupuzor or Forigerimod (IPP 201101 or CEP 33457), has been extensively studied.2018年3月2日—Conclusion. These findings show thatP140down-regulates HLA class II overexpression in human lupus B cells, and also thatP140hampers the ... Early phase II clinical trials have shown promising results in patients with SLE. For instance, studies involving patients with moderately active SLE have administered P140 peptide via subcutaneous injections, with findings suggesting that a longer treatment period might be necessary to achieve a higher number of responders.

Data from these trials indicate that P140 peptide acts by depleting hyper-activated autoreactive T and B cells, leading to the restoration of normal immune homeostasisThe Spliceosomal Phosphopeptide P140 Controls .... Research has also shown that peptide P140 can transiently abolish T cell reactivity, a key factor in autoimmune exacerbations. Furthermore, P140 peptide has been found to down-regulate HLA class II overexpression in human lupus B cells and hamper their activation.作者：R Zimmer·2013·被引用次数：201—A longer treatment period appears necessary to increase the number of responders. Thepeptide P140/Lupuzor is a promiscuous MHC class II binder that is ...

The safety and tolerability of the spliceosomal peptide P140 have been evaluated in clinical trials involving hundreds of patients with SLE, with no significant adverse events reported.Description. Thepeptideis used to block Anti-p140Cap Antibody (orb304606) reactivity. Research Area. Epigenetics. Images & Validation. −.p140Cappeptide... The P140 peptide is considered a completely new type of compound compared to existing treatments for lupus作者：N Schall·2022·被引用次数：10—Data indicate thatP140acts by depleting hyper-activated autoreactive T and B cells and restores normal immune homeostasis.. Its efficacy has been observed to be significant in ameliorating both clinical and biological manifestations of the disease作者：N Page·2009·被引用次数：81—The phosphopeptideP140issued from the spliceosomal U1-70K snRNP protein is recognized by lupus CD4 + T cells, transiently abolishes T cell reactivity..

Broader Therapeutic Potential Beyond Lupus

While SLE has been a primary focus for P140 peptide research, preliminary studies suggest its potential in other conditions as well. Investigations into its effect on inflammatory responses in models of gout indicate a broader applicability of this immunomodulatory peptide. The mechanism of action, involving the modulation of autoreactivity and immune cell function, could be beneficial in other autoimmune diseases such as rheumatoid arthritis and Sjögren's syndrome, where T cells recognize similar U1-70K epitopesAbstract P140: A Novel New Generation Designer ....

Formulation and Future Directions

The formulation of P140 peptide has also been a subject of research. Studies have explored different excipients, such as mannitol and trehalose, to optimize its stability and deliveryLupus Regulator Peptide P140 Represses B Cell .... The P140 peptide is a promiscuous MHC class II binder, contributing to its broad impact on the immune system作者：N Page·2011·被引用次数：132—P140 peptideis a 21-mer fragment of the spliceosomal U1-70K small nuclear ribonucleoprotein protein that significantly ameliorates clinical and biological .... Ongoing research continues to elucidate the full spectrum of its therapeutic effects and to determine optimal dosing and treatment durations for various autoimmune conditions. The development of the P140 peptide represents a significant advancement in the field of peptide-based therapeutics and offers a beacon of hope for individuals suffering from debilitating autoimmune disorders作者：R Zimmer·2013·被引用次数：201—A longer treatment period appears necessary to increase the number of responders. Thepeptide P140/Lupuzor is a promiscuous MHC class II binder that is ....